Alpha 2.0
Login Register
» Authors » T Hickish

T Hickish

Explore the profile of T Hickish including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 61
Citations 2001
Followers 0
Related Specialties
Oncology
General Medicine
Gastroenterology
Top 10 Co-Authors
D Cunningham
M Nicolson
T Iveson
M Hill
A Norman
P Harper
S Milan
A R Norman
I Chau
J Oates
Published In
Ann Oncol
Br J Cancer
J Clin Oncol
Lancet
Eur J Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer
Turner N, Swift C, Jenkins B, Kilburn L, Coakley M, Beaney M, et al.
Ann Oncol . 2022 Nov; 34(2):200-211. PMID: 36423745
Background: Post-treatment detection of circulating tumour DNA (ctDNA) in early-stage triple-negative breast cancer (TNBC) patients predicts high risk of relapse. c-TRAK TN assessed the utility of prospective ctDNA surveillance in...
2.
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
Earl H, Hiller L, Dunn J, Blenkinsop C, Grybowicz L, Vallier A, et al.
Ann Oncol . 2017 May; 28(8):1817-1824. PMID: 28459938
Background: The ARTemis trial previously reported that addition of neoadjuvant bevacizumab (Bev) to docetaxel (D) followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC) in HER2 negative breast cancer improved the pathological...
3.
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al.
Ann Oncol . 2013 May; 24(9):2278-84. PMID: 23704196
Background: Pertuzumab (P) combined with trastuzumab (H)-based chemotherapy improves efficacy in early and advanced HER2-positive breast cancer. We assessed the tolerability, with particular focus on cardiac safety, of H and...
4.
Interactions in the aetiology, presentation and management of synchronous and metachronous adenocarcinoma of the prostate and rectum
Nash G, Turner K, Hickish T, Smith J, Chand M, Moran B
Ann R Coll Surg Engl . 2012 Oct; 94(7):456-62. PMID: 23031761
Adenocarcinoma of the prostate and rectum are common male pelvic cancers and may present synchronously or metachronously due to their anatomic proximity. The treatment of rectal or prostate cancer (in...
5.
Changes in cancer incidence and mortality in England and Wales and a comparison of cancer deaths in the major developed countries by age and sex 1979-2002 in context of GDP expenditure on health
Pritchard C, Hickish T
Ecancermedicalscience . 2012 Jan; 2:80. PMID: 22275969
Background: The successful treatment of cancer is a major health and political issue for England and Wales and the major developed countries (MDCs). All malignancy deaths by age and sex...
6.
Comparing cancer mortality and GDP health expenditure in England and Wales with other major developed countries from 1979 to 2006
Pritchard C, Hickish T
Br J Cancer . 2011 Oct; 105(11):1788-94. PMID: 21970877
Background: Cancer and gross-domestic-product on health expenditure (GDPHE) are critical issues for major developed countries (MDC). Each country's economic input, GDPHE 1980-2005 is contrasted with clinical outputs, cancer mortality rates...
7.
A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection
Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, et al.
Ann Oncol . 2011 Feb; 22(9):2042-2048. PMID: 21285134
Background: Perioperative chemotherapy improves outcome in resectable colorectal liver-only metastasis (CLM). This study aimed to evaluate perioperative CAPOX (capecitabine-oxaliplatin) plus bevacizumab in patients with poor-risk CLM not selected for upfront...
8.
Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study
Houston S, Grieve R, Hickish T, Percival F, Hamilton E
J Med Econ . 2010 Feb; 13(1):162-7. PMID: 20136578
Aims: To describe renal function monitoring practice in patients with metastatic bone disease (MBD) treated with IV zoledronic acid (ZA) and oral ibandronic acid (IA), the management pathways and NHS...
9.
A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial
Sirohi B, AHern R, Coombes G, Bliss J, Hickish T, Perren T, et al.
Ann Oncol . 2010 Jan; 21(8):1623-1629. PMID: 20093351
Background: The epirubicin with cisplatin and infusional 5-fluorouracil (5-FU) (ECisF) regimen was found to be highly active in the treatment of metastatic breast cancer and as neoadjuvant therapy. The UK...
10.
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials
Chau I, Norman A, Cunningham D, Oates J, Hawkins R, Iveson T, et al.
Ann Oncol . 2009 Jan; 20(5):885-91. PMID: 19164454
Background: It is unclear if differential chemotherapy effects exist on overall survival (OS), response rate (RR) and toxicity depending on primary tumour origin [oesophageal versus oesophago-gastric junction (OGJ) versus gastric...